{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Joanne Reeve, Michelle Maden, Ruaraidh Hill, Amadea Turk, Kamal Mahtani, Geoff Wong, Dan Lasserson, Janet Krska, Dee Mangin, Richard Byng, Emma Wallace & Ed Ranson.

Joanne Reeve ^1,*, Michelle Maden ², Ruaraidh Hill ², Amadea Turk ³, Kamal Mahtani ³, Geoff Wong ³, Dan Lasserson ⁴, Janet Krska ⁵, Dee Mangin ⁶, Richard Byng ⁷, Emma Wallace ⁸, Ed Ranson ⁹

¹ Academy of Primary Care, Hull York Medical School, University of Hull, Hull, UK
² Liverpool Reviews and Implementation Group, Institute of Population Health, University of Liverpool, Liverpool, UK
³ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
⁴ Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK
⁵ Medway School of Pharmacy, Universities of Greenwich and Kent, Chatham, UK
⁶ Department of Family Medicine, McMaster University, Hamilton, ON, Canada
⁷ Community and Primary Care Research Group, Peninsula Medical School, University of Plymouth, Plymouth, UK
⁸ Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland
⁹ , Liverpool, UK
^* Corresponding author Email: Joanne.Reeve@hyms.ac.uk

Declared competing interests of authors: Ruaraidh Hill declares a financial, non-personal, non-specific interest, having delivered educational workshops on health economics, medicines management and health technology assessment for cancer specialists supported by unrestricted sponsorship by the pharmaceutical industry and an industry association (March 2019). No fees were received personally and the workshops were not specific to the topic of this research. Kamal Mahtani declares membership of the following groups: Health Technology Assessment (HTA) Primary Care, Community and Preventative Interventions (PCCPI) Panel (2018), HTA Prioritisation Committee A (Out of hospital) (2018 to present), HTA Prioritisation Committee A Methods Group (2018) and HTA Programme Oversight Committee (2018–21). Geoff Wong declares membership of the following groups: HTA PCCPI Panel (2015–18), Pharmaceuticals Panel (2011–15), HTA Prioritisation Committee A (Out of hospital) (2015–21) and HTA Prioritisation Committee A Methods Group. Dan Lasserson declares membership of the HTA Clinical Evaluation and Trials Committee (2016–21).